GVR Report cover Intravenous Solutions Market Size, Share & Trends Report

Intravenous Solutions Market Size, Share & Trends Analysis Report By Type (TPN, PPN), By Nutrients (Carbohydrates, Single Dose Amino Acid Solution, Parenteral Lipid Emulsion), By Region, And Segment Forecasts, 2021 - 2028

  • Published Date: Feb, 2021
  • Base Year for Estimate: 2020
  • Report ID: GVR-1-68038-137-5
  • Format: Electronic (PDF)
  • Historical Data: 2016 - 2019
  • Number of Pages: 114

Report Overview

The global intravenous solutions market size was valued at USD 10.7 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 7.9% from 2021 to 2028. The prevalence of malnutrition, especially among the elderly population due to chronic diseases such as cancer is expected to boost demand for IV solutions in the years to come. Dehydration is one of the common side effects of cancer. Chemotherapy causes dehydration due to side effects, such as vomiting, diarrhea, or excessive urination, which boosts the need for IV hydration.

U.S. IV solutions market size, by type, 2016 - 2028 (USD Billion)

Apart from this, in diseases such as diarrhea, which results in depleting fluids from the body, demand for IV solutions is expected to increase. Over a billion cases of childhood diarrheal disease are reported each year. However, IV solutions are preferred only in severe cases, else Oral Rehydration Therapy (ORS) is preferred.

In addition, many premature babies receive nutrition through IV solutions. In the U.S., after steady declines till 2014, there has been a consistent increase in the preterm birth rate. In 2019, preterm birth affected 1 of every 10 infants born in the country. These IV solutions are tailored for each baby. The fluid contains calories, proteins, and electrolytes. Thus, with the increase in the number of premature births, demand for IV solutions is expected to increase.

Intravenous solutions constitute a vital part of the U.S. healthcare system, enabling doctors and nurses to help hydrate their patients, replace lost blood volume, and administer drugs. However, in recent years, the country’s supplies have been severely affected due to longer and more dangerous influenza seasons and destructive weather events. The intravenous solutions shortages have approached crisis levels, forcing healthcare providers to either delay patient treatment or use an alternate technique. In the U.S., IV solutions are provided by a small number of suppliers. Baxter and B. Braun Medical supply most of the IV solutions in the country. Production or quality issues at the manufacturing facilities of these companies cause the overall shortage of IV solutions in the country. Thus, high growth chances lie ahead for intravenous solutions manufacturers to bridge the demand-supply gap.

In view of this shortage, in 2019, leading player B. Braun Medical Inc., invested USD 1.0 billion to lessen intravenous solutions shortages in the U.S. Under the investment plan, the company will, open a new manufacturing plant, update an existing facility, and expand production at one of its factories in the country.

The COVID-19 pandemic has increased the demand for intravenous solutions. Intensive Care Units (ICU) worldwide are overwhelmed with patients infected with COVID-19. Recently, reports of the new coronavirus strain have emerged in the U.K., thereby causing a second wave of the pandemic. This in turn shall lead to an increasing number of hospital admissions in the country. Many of the patients, especially the elder population are put on ventilators. In such cases, nutrition is given through intravenous solutions. Moreover, the WHO has also recommended patients with COVID-19 in respiratory failure should be treated with intravenous fluids, especially in mechanical ventilation settings. Thus, demand for IV solutions is expected to spike, especially during the pandemic.

Type Insights

The TPN segment dominated the market and accounted for the largest revenue share of about 65.8% in 2020 and is projected to continue its dominance over the forecast period. Based on the type of nutrition, the market is segmented into Total Parenteral Nutrition (TPN) and Peripheral Parenteral Nutrition (PPN).

The TPN segment is also projected to grow rapidly owing to its increased importance in the treatment of chronic inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, which affects around 1.6 million in the U.S. each year. TPN helps maintain adequate nutrition in the body and correct malnutrition in patients with dysfunctional digestive systems.

Nutrients Insights

The single dose amino acid solution segment dominated the market and accounted for the largest revenue share of about 31.4% in 2020 and is projected to continue its dominance over the forecast period. Based on nutrients, the market is segmented into carbohydrates, single dose amino acid solution, vitamins and minerals (salt and electrolyte), parenteral lipid emulsion.

The rising prevalence of kidney failure, protein deficiency diseases (Marasmus and kwashiorkor), and hepatic diseases is contributing to the high consumption of amino acid injections. Moreover, increased approvals of enhanced amino acids with fewer adverse effects are also fueling the market growth.

Global IV solutions market share, by nutrients, 2020 (%)

The vitamins and minerals (salts and electrolytes) segment is expected to witness the highest CAGR of 9.7% over the forecast period. Key factors contributing to its elevated growth include an increasing number of surgeries and post-operative nutritional management; treatment of diseases, such as anemia, beriberi, and pellagra, and chronic mental conditions; and replacement therapies.

Regional Insights

Based on geography, North America dominated the market and accounted for the largest revenue share of 40.8% in 2020.The U.S. is the most important market and accounts for the maximum revenue share in the region. The country is backed by a leading player, Baxter, which supplies around 50.0% of the IV solutions in hospitals across the country. However, the country still faces a shortage of intravenous (IV) solutions, due to influenza seasons, highlighting the need for intravenous (IV) solutions in the country.

Asia Pacific is projected to be the fastest growing region during the forecast period with India being one of the fastest-growing nations.24% of the global preterm births occur in India, which represents a total of 3.5 million preterm births every year. Infants born premature are at a higher risk poor growth and catching infections. Hence, early parenteral nutrition is vital for preterm infants and must supply adequate amino acids and energy. Thus, India is expected to be a key revenue generator for the intravenous (IV) solutions market in the coming years.

Key Companies & Market Share Insights

The key companies provide a wide range of products with different compositions specific to different disease conditions. In June 2020, JW Holdings formed a partnership with Baxter to export its parenteral nutrition (PN) products to U.S. market. Under the terms of the agreement, JW Life Science, a subsidiary of JW Holdings, developed parenteral nutrition (PN) for Baxter. Baxter was responsible for the local distribution and marketing of the product in the U.S. market. The partnership is expected to help in bridging the gap between the demand and supply gap of intravenous solutions in the country. Some of the prominent players in the intravenous solutions market include:

  • Hospira

  • Terumo Corporation

  • B. Braun Melsungen AG

  • Fresenius Kabi

  • Baxter

Intravenous Solutions Market Report Scope

Report Attribute


Market size value in 2021

USD 11.1 billion

Revenue share in 2028

USD 18.9 billion

Growth rate

CAGR of 7.9% from 2021 to 2028

Base year for estimation


Historical data

2016 - 2019

Forecast period

2021 - 2028

Quantitative units

Revenue in USD million and CAGR from 2021 to 2028

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments covered

Type, nutrients, region

Regional scope

North America; Europe; Asia Pacific; Latin America; Middle East and Africa

Country scope

U.S.; Canada; U.K.; Germany; France; Russia; Switzerland; China; India; Japan; Australia; South Korea; Mexico; Brazil; South Africa

Key companies profiled

Hospira; Terumo Corporation; B. Braun Melsungen AG; Fresenius Kabi; Baxter

Customization scope

Free report customization (equivalent to up to 8 analysts’ working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2028. For the purpose of this study, Grand View Research has segmented the global intravenous solutions market on the basis of type, nutrients, and region:

  • Type Outlook (Revenue, USD Million, 2016 - 2028)

    • Total Parenteral Nutrition (TPN)

    • Peripheral Parenteral Nutrition (PPN)

  • Nutrients Outlook (Revenue, USD Million, 2016 - 2028)

    • Carbohydrates

    • Single Dose Amino Acid Solution

    • Vitamins & Minerals (Salt and electrolyte)

    • Parenteral Lipid Emulsion

    • Others

  • Regional Outlook (Revenue, USD Million, 2016 - 2028)

    • North America

      • U.S.

      • Canada

    • Europe

      • U.K.

      • Germany

      • France

      • Russia

      • Switzerland

    • Asia Pacific

      • Japan

      • China

      • India

      • Australia

      • South Korea

    • Latin America

      • Brazil

      • Mexico

    • Middle East & Africa

      • South Africa

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.